KRAS G12C is a distinctively aggressive, poor survival tumor genotype conferring resistance to anti-EGFR therapies in lung, colorectal (CRC), and pancreatic cancers. Prospective therapies targeting G12C have demonstrated promising activity in Phase I trials.
Drugging the undruggable: a market readiness analysis for KRAS-G12C
Drugging the undruggable: a market readiness analysis for KRAS-G12C
30 June, 2020